Molecular Tumor Boards: Where the Room Gets Bigger
This blog entry came from research into the evolution from Tumor Boars to Molecular Tumor Boards. UCSD in San Diego played an important role in this patient-focused progress.
SOURCE: https://pmc.ncbi.nlm.nih.gov/articles/PMC5760337/?utm_source=chatgpt.com
For a long time, cancer care has felt like a series of rooms. The scan room. The infusion room. The pathology room. The waiting room, which is somehow always the largest room of all. A traditional tumor board was one of the better rooms: doctors from different specialties gathered around a patient’s case and asked, “What are we seeing, and what should we do next?” But this article describes the next room opening — the Molecular Tumor Board. Same patient. Same fear. Same urgency. But now the room includes genomics, immunology, bioinformatics, pathology, radiology, clinical trials, and people who understand that cancer is not just where it appears on a scan, but what may be driving it underneath the hood.
That history matters. Tumor boards have long been one of medicine’s better ideas: put more than one set of expert eyes on a hard case. Surgeons see one kind of truth. Medical oncologists see another. Radiation oncologists, pathologists, and radiologists each bring their own lantern into the room. The Molecular Tumor Board does not replace that. It expands it. In the UCSD model described in the article, the table grew to include geneticists, bioinformatics specialists, translational scientists, immunology experts, and even supercomputer modeling. That is not just fancy medicine. That is a search party.
This matters to me because rare cancer has a way of making standard pathways feel too narrow. A Molecular Tumor Board does not promise a miracle, and I do not trust anything in cancer that comes wrapped like a miracle. What it offers is something more useful: more eyes, more disciplines, more questions, and a better chance that no important clue gets left on the floor. It asks whether a tumor’s molecular profile might point toward a targeted drug, an immunotherapy, a clinical trial, radiation, chemotherapy, or some thoughtful combination. In patient language, it asks: are we treating only the location of the cancer, or are we also paying attention to the machinery that may be helping it survive?
This is also where newer assays begin to matter. Broad-based genomic sequencing, or BGS, looks across many cancer-related genes rather than checking only one or two familiar targets. Tempus xT is a tumor DNA sequencing assay that can help identify mutations, copy number changes, rearrangements, and other genomic alterations in tumor tissue. Tempus xR means RNA sequencing, with “RNA” standing for ribonucleic acid; it can help show which genes are being actively expressed and may help identify gene fusions or other signals that DNA testing alone might miss. Circulating tumor DNA, or ctDNA, refers to tiny fragments of tumor-derived DNA that can be found in the bloodstream. In my language: broad-based genomic sequencing surveys the battlefield, xT studies the enemy’s wiring, xR listens for which wires are humming, and ctDNA looks for footprints in the hallway.
Signatera fits into this conversation in a different but important way. Signatera is a personalized, tumor-informed circulating tumor DNA test, meaning it is built from the molecular fingerprint of a person’s own tumor and then used through blood draws to look for molecular signs of residual disease or recurrence. It is not the same as a scan, and it is not a crystal ball. But for patients living between scans, ctDNA can become part of the listening system. A CT scan may show what has grown large enough to be seen. A tumor-informed ctDNA test may sometimes suggest that cancer activity is present before imaging has something obvious to point at. That does not automatically mean treatment should begin, but it may mean the conversation should sharpen.
The article’s most important warning is timing. Precision oncology is less helpful if the information arrives after the patient has already deteriorated, after the cancer has already moved, after everyone is suddenly running instead of planning. That line hit me hard. For a cancer patient, especially a rare-cancer patient, the question should not only be, “What do we do when the scan changes?” It should also be, “What information do we need before the scan changes?” A Molecular Tumor Board, supported by tools like broad-based genomic sequencing, Tempus xT, Tempus xR, Signatera, and circulating tumor DNA monitoring, can help move the conversation from passive surveillance to active planning. Not reckless treatment. Not panic. Not pretending blood tests are prophecy. Just better listening. Earlier listening.
The kind of listening that says: let’s not wait until the fire is in the hallway before we look for smoke.
—Ty